8-K filed Nov 4, 2026 at 16:05 ET
Personalis reported Q3 2026 total revenue of $25.6M, up 77% YoY from $14.5M, driven by clinical test revenue surging to $4.4M from $0.4M and population sequencing revenue of $4.0M vs $0.2M. Net loss widened to $33.8M from $21.7M, with SG&A expense doubling to $26.0M largely due to merger-related costs. The company withdrew guidance and will not hold an earnings call due to the pending Tempus acquisition announced July 20, 2026.